Home> Our Vision
Registration of novel drug compounds is increasingly difficult, costly, and time-consuming. This prevents many patients from receiving the right treatment in time. This is particularly true of compounds targeting small patient populations, as is often the case with hematologic malignancies (HMs). Thus, many patients with HMs have unmet needs that must be urgently addressed.
One important barrier to drug registration is the need to establish outcome criteria, such as overall survival rates, which is hard to do with extremely small patient populations. As a result, promising new treatments are delayed or are considered to be too costly to develop. This situation calls for more efficient treatment development and regulatory evaluation. We trust that, by making use of Big Data technologies, we can accelerate more efficient drug development, regulatory evaluation, access appraisal, and treatment strategies.
Part of the solution lies in developing new tools that allow us to perform the analysis of Big Data. This requires a concerted action on the part of a multidisciplinary partnership of stakeholders. The HARMONY Alliance, a European Network of Excellence for Big Data in Hematology, was established to make this happen. HARMONY will enable the collection of a critical mass of data on the recent developments in pharmacology as well as in real-time, real-life hematology. We believe that Big Data will empower clinicians, patients, and policy stakeholders to develop better therapy access and improved care for patients with various HMs by:
HARMONY focuses on the following seven hematologic malignancies: Acute lymphoblastic leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkins Lymphoma, Multiple Myeloma and Pediatric Hematologic Malignancies. Read more about each of the 7 diseases >>